MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis
- PMID: 26416448
- PMCID: PMC4741711
- DOI: 10.18632/oncotarget.5324
MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis
Abstract
This is a systematic review of studies investigating the prognostic value of different microRNAs (miRs) in renal cell carcinoma (RCC). Twenty-seven relevant studies were identified, with a total of 2578 subjects. We found that elevated expression of miR-21, miR-1260b, miR-210, miR-100, miR-125b, miR-221, miR-630, and miR-497 was associated with a poor prognosis in RCC patients. Conversely, decreased expression of miR-106b, miR-99a, miR-1826, miR-215, miR-217, miR-187, miR-129-3p, miR-23b, miR-27b, and miR-126 was associated with a worse prognosis. We performed meta-analyses on studies to address the prognostic value of miR-21, miR-126, miR-210, and miR-221. This revealed that elevated miR-21 expression was associated with shorter overall survival (OS; hazard ratio [HR], 2.29; 95% confidence interval [CI], 1.28-4.08), cancer specific survival (CSS; HR, 4.16; 95% CI, 2.49-6.95), and disease free survival (DFS; HR, 2.15; 95% CI, 1.16-3.98). The decreased expression of miR-126 was associated with shorter CSS (HR, 0.35; 95% CI, 0.15-0.85), OS (HR, 0.45; 95% CI, 0.30-0.69), and DFS (HR 0.30; 95% CI, 0.18-0.50). Our comprehensive systematic review reveals that miRs, especially miR-21 and miR-126, could be promising prognostic markers and useful therapeutic targets in RCC.
Keywords: meta-analysis; microRNA; prognosis biomarker; renal cell carcinoma; survival.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes.J Cancer Res Clin Oncol. 2014 Aug;140(8):1295-304. doi: 10.1007/s00432-014-1690-7. Epub 2014 May 7. J Cancer Res Clin Oncol. 2014. PMID: 24802708 Free PMC article.
-
The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.Urol Oncol. 2014 Jan;32(1):50.e1-8. doi: 10.1016/j.urolonc.2013.07.016. Epub 2013 Nov 13. Urol Oncol. 2014. PMID: 24239465
-
Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Clin Lab. 2016 Nov 1;62(11):2203-2211. doi: 10.7754/Clin.Lab.2016.160426. Clin Lab. 2016. PMID: 28164670
-
MicroRNAs as prognostic molecular signatures in human head and neck squamous cell carcinoma: a systematic review and meta-analysis.Oral Oncol. 2015 Apr;51(4):321-31. doi: 10.1016/j.oraloncology.2015.01.008. Epub 2015 Feb 9. Oral Oncol. 2015. PMID: 25677760
-
Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: a literature review.Diagnosis (Berl). 2021 Oct 22;9(2):157-165. doi: 10.1515/dx-2021-0080. Diagnosis (Berl). 2021. PMID: 34674417
Cited by
-
Prognostic role of microRNA-21 expression in gliomas: a meta-analysis.J Neurooncol. 2016 Oct;130(1):11-17. doi: 10.1007/s11060-016-2233-7. Epub 2016 Aug 16. J Neurooncol. 2016. PMID: 27531352 Review.
-
miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma.Kidney Cancer. 2019 Aug 7;3(2):119-132. doi: 10.3233/KCA-190051. Kidney Cancer. 2019. PMID: 31763513 Free PMC article.
-
A tumor-suppressive microRNA, miRNA-485-5p, inhibits glioma cell proliferation and invasion by down-regulating TPD52L2.Am J Transl Res. 2017 Jul 15;9(7):3336-3344. eCollection 2017. Am J Transl Res. 2017. PMID: 28804551 Free PMC article.
-
microRNA-630 Regulates Underglycosylated IgA1 Production in the Tonsils by Targeting TLR4 in IgA Nephropathy.Front Immunol. 2020 Nov 26;11:563699. doi: 10.3389/fimmu.2020.563699. eCollection 2020. Front Immunol. 2020. PMID: 33324395 Free PMC article.
-
Plasma miR-187* is a potential biomarker for oral carcinoma.Clin Oral Investig. 2017 May;21(4):1131-1138. doi: 10.1007/s00784-016-1887-z. Epub 2016 Jun 20. Clin Oral Investig. 2017. PMID: 27324473
References
-
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64:9–29. - PubMed
-
- Murai M, Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol. 2004;14:229–233. - PubMed
-
- Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–2490. - PubMed
-
- Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011;59:18–23. - PubMed
-
- Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T, Wild PJ. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol. 2009;56:636–643. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical